Evidence map›Paper›PMID 42699526›Full record

ArticleJTO clinical and research reports2026

Chi-Lu Chiang, Ying-Ting Liao, Yi-Chen Yeh, Ruei-Lin Sun, Hsu-Ching Huang, Yung-Hung Luo, Chia-I Shen, Heng-Sheng Chao, Yen-Han Tseng, Tsu-Hui Shiao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chi-Lu ChiangDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Ying-Ting LiaoDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Yi-Chen YehSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Ruei-Lin SunDivision of Pulmonology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Hsu-Ching HuangDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Yung-Hung LuoDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Chia-I ShenDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Heng-Sheng ChaoDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Yen-Han TsengDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Tsu-Hui ShiaoDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Ruihong WangThoracic Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Haitao WangThoracic Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
David S SchrumpThoracic Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Yuh-Min ChenSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Transformed small-cell lung cancer (tSCLC) is a clinically important resistance mechanism to EGFR tyrosine kinase inhibitors in Methods: Data from 45 patients with Results: Most patients were women (60%) and never-smokers (75.6%). Exon 19 deletion was the predominant Conclusions: tSCLC remains an aggressive resistance phenotype with poor outcomes. EP-based combination strategies may provide clinical benefit, whereas frequent DLL3 expression supports further evaluation of targeted therapies.

Indexed as

Delta-like ligand 3Epidermal growth factor receptorImmune checkpoint inhibitorNon–small cell lung cancerSmall cell transformation

Identifiers

PMID42699526
PMCPMC13543798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.